Today: November 22, 2017, 10:50 pm
  
Business

Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering

PR-Inside.com: 2017-11-09 00:35:01

MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited ("Telix", the "Company"), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly supported by institutional investors internationally and domestically, as well as by retail investors in Australia.

Telix's shares are due to begin trading on the Australian Securities Exchange (ASX) on 15th November 2017 under the ticker code TLX. The IPO, with a total of 77.0 million shares issued at $0.65 per share, gives Telix a market capitalisation of $128 million. The IPO was fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited.

The IPO was also strongly supported by existing shareholders, which include both industry partners and domestic institutional investors such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Alium Capital Management and Allan Moss. Fidelity International is a cornerstone investor in the IPO and will hold approximately 10% of the issued capital of the Company upon completion of the IPO.

Telix Co-Founder and CEO Dr. Christian Behrenbruch said the company was delighted with the strong support from investors.

"We would like to thank both existing and new investors for their support of the IPO and look forward to sharing the next phase of our journey with our shareholders. With established clinical data and several well-defined value inflection points in the coming months, this financing will enable Telix to deliver significant clinical and commercial outcomes."

Telix Co-Founder and Chief Medical Officer Dr. Andreas Kluge noted, "We started the Telix journey over two years ago with the goal of creating momentum in a field of medicine that has great clinical potential but is only just starting to hit its commercial stride. We have built a company that we believe will have meaningful patient impact in disease areas with major unmet diagnostic and therapeutic need."

Proceeds from the IPO will provide capital to fund the development and completion of clinical trials for Telix's pipeline in renal (kidney), prostate and brain cancer (glioblastoma), and assist the Company to complete multiple clinical and product development milestones over the next 24 months.

Telix Pharmaceuticals Limited

Dr Christian Behrenbruch

Telix Pharmaceuticals

Email: chris@telixpharma.com

Investor and Media Relations

Kyahn Williamson

WE Buchan

Tel: +61 (3) 9866 4722

Email: kwilliamson@buchanwe.com.au




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Telix Pharmaceuticals Limited via Globenewswire




# 567 Words
Related Articles
More From The Author
Mandalay Resources Corporation Announces Third Quarter Financial [..]
TORONTO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) [..]
Fortuna reports consolidated financial results for the [..]
VANCOUVER, British Columbia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) today reported net [..]
Enstar Group Limited Reports Third Quarter Results
HAMILTON, Bermuda, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Enstar Group Limited (Nasdaq:ESGR) filed its quarterly report on Form 10-Q [..]
Medtronic Announces Preliminary Second Quarter Revenue
Preliminary Revenue of Approximately $7.1 Billion Company Updates Hurricane Maria Impact to Second Quarter Financial Results Company [..]
NL REPORTS THIRD QUARTER 2017 RESULTS
DALLAS, TEXAS - November 8, 2017 - NL Industries, Inc. (NYSE: NL) today reported net income attributable to NL stockholders [..]
 
More From Business
Nets Group launches JCB's J/Speedy NFC mobile [..]
Copenhagen and Tokyo, Nov 21, 2017 - (ACN Newswire) - The Nets Group and JCB International Co. Ltd. (JCBI), the [..]
JCB Special Offer at Changi's Mystical Garden [..]
SINGAPORE, Nov 17, 2017 - (ACN Newswire) - Changi Airport has teamed up with Sanrio, creators of characters beloved around [..]
Destination EU2018: Lithuania and Singapore Forge New [..]
SINGAPORE / VILNIUS, Nov 15, 2017 - (ACN Newswire) - Invest Lithuania and Singapore FinTech Association today signed a landmark [..]
Hong Leong Finance Chooses Kamakura's Risk Management [..]
Asset and Liability Management, Fund Transfer Pricing, and Liquidity Management SINGAPORE, Nov 14, 2017 - (ACN Newswire) - [..]
Tenant Direct- Letting Agents Southampton
Tenant Direct- Letting Agents Southampton Looking for the help of letting agents in Southampton? When it comes to finding a [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.